National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Care Management (1)
- Children/Adolescents (4)
- Chronic Conditions (1)
- COVID-19 (1)
- (-) Evidence-Based Practice (12)
- Guidelines (2)
- Healthcare Costs (1)
- Health Services Research (HSR) (1)
- Newborns/Infants (1)
- Nutrition (1)
- Outcomes (2)
- Patient-Centered Outcomes Research (8)
- Research Methodologies (1)
- Respiratory Conditions (1)
- Risk (1)
- Screening (1)
- (-) Skin Conditions (12)
- Sleep Problems (1)
- Tobacco Use (1)
- Treatments (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 12 of 12 Research Studies DisplayedFishbein AB, Lor J, Penedo FJ
Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross-sectional study of the patient reported outcomes measurement information system pediatric sleep measures and actigraphy.
The purposes of this cross-sectional study were to test the Patient-Reported Outcomes Measurement Information System (PROMIS) sleep measures in pediatric atopic dermatitis (AD) and to develop an algorithm to screen, evaluate, and intervene to reduce sleep disturbances. Participants were children with AD aged 5 to 17 and one parent who completed sleep, itch, and AD-specific questionnaires. Clinicians assessed disease severity. PROMIS sleep disturbance parent proxy reliability was high and was differentiated among Patient-Oriented Eczema Measure (POEM)-determined disease severity groups. The authors concluded that sleep disturbance in pediatric AD should be screened using the POEM sleep question, and further assessment using the PROMIS sleep disturbance measure or objective sleep monitoring if it is needed.
AHRQ-funded; HS023011.
Citation: Fishbein AB, Lor J, Penedo FJ .
Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross-sectional study of the patient reported outcomes measurement information system pediatric sleep measures and actigraphy.
J Am Acad Dermatol 2023 Feb; 88(2):348-56. doi: 10.1016/j.jaad.2020.05.138..
Keywords: Children/Adolescents, Sleep Problems, Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice
Silverberg JI, Lei D, Yousaf M
What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study.
This prospective observational study’s objective was to determine the minimal important changes (MICs) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD) across all severities of atopic dermatitis (AD). Questionnaires and evaluation by a dermatologist (n =826) were used to determine the MIC of percentage and absolute improvement of EASI and SCORAD scores in adults and children. Absolute MICs for EASI, SCORAD, and O-SCORAD varied by baseline severity and EASI 50, SCORAD 35 and O-SCORAD 35 were meaningful percentage MICs regardless of baseline AD severity.
AHRQ-funded; HS023011.
Citation: Silverberg JI, Lei D, Yousaf M .
What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study.
Br J Dermatol 2021 May;184(5):888-95. doi: 10.1111/bjd.19457..
Keywords: Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice
Silverberg JI, Lei D, Yousaf M
Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.
This study’s goal was to determine the measurement properties of the product of validated Investigator’s Global Assessment for AD and body surface area (vIGA*BSA) for atopic dermatitis (AD) severity. The authors performed a prospective practice-based study using questionnaires and evaluation by a dermatologist (n = 653). The vIGA*BSA can also be divided into six categories (vIGA*cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%)). The assessment was compared with other rating scales such as SCORAD, Patient-Oriented Eczema Measure, Dermatology Life Quality Index, ItchyOOL, PROMISE Sleep Disturbance, and sleep-related impairment. Scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD.
AHRQ-funded; HS023011.
Citation: Silverberg JI, Lei D, Yousaf M .
Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.
J Eur Acad Dermatol Venereol 2021 Jan;35(1):180-87. doi: 10.1111/jdv.16846..
Keywords: Children/Adolescents, Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice
Silverberg JI, Lei D, Yousaf M
Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis.
This study looked at the measurement properties of the Rajka-Langeland severity score for atopic dermatitis (AD) in children and adults and compared it with other clinician-reported outcomes. The study used questionnaires and evaluation by a dermatologist (n = 427). Rajka-Langeland had good concurrent validity with the Eczema Area and Severity Index and body surface area; good convergent validity with the numeric rating scale average-itch and worst-itch, Patient-Oriented Eczema Measure, Dermatology Life Quality Index, Patient Reported Outcomes Measurement Information System Itch Questionnaire in adults and/or children; fair discriminant validity for patient- and physician reported global AD severity; good responsive to change of severity of AD and itch; and good reliability, internal consistency; with no floor or ceiling effects.
AHRQ-funded; HS023011.
Citation: Silverberg JI, Lei D, Yousaf M .
Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis.
Br J Dermatol 2021 Jan;184(1):87-95. doi: 10.1111/bjd.19159..
Keywords: Children/Adolescents, Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice
Hong MR, Lei D, Yousaf M
A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice.
This study examined the longitudinal course of adult atopic dermatitis (AD) severity in clinical practice. Dermatology patients were assessed at approximately 6,12, 18, and 24 months by the scoring systems Eczema Area and Severity Index (EASI) and objective-Scoring Atopic Dermatitis (objective-SCORAD). At any visit, 36.2% of cases were scored as moderate, and 18.2% were severe. Among those patients, 25% and 18.6% continued to have moderate or severe scores at 1 or more follow-up visits for EASI, and 22.6% and 24.5% moderate or severe objective-SCORAD scores respectively. Many patients had fluctuating severity scores over time and a minority had persistently moderate or severe lesions over time, and most of those patients were unable to achieve persistent lesional clearance.
AHRQ-funded; HS023011.
Citation: Hong MR, Lei D, Yousaf M .
A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice.
Ann Allergy Asthma Immunol 2020 Dec;125(6):686-92.e3. doi: 10.1016/j.anai.2020.07.005.
.
.
Keywords: Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice
Gelfand JM, Armstrong AW, Bell S
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Vversion 1.
This article describes the process that was used to create the first version of a guidance document for management of psoriatic disease during the COVID-19 pandemic developed by the National Psoriasis Foundation. A task force of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was created with supplementation by nonvoting members. A Delphi process was created, out of which 22 guidance statements were approved. All guidance statements were recommended, with 9 of them high consensus, and the remaining 13 were moderate consensus. Topics covered included how COVID-19 can impact patients, how medical care can be optimized during the pandemic, and what patients can do to lower their risk of getting infected with COVID-19. This guidance will be updated by the TF as new data emerges.
AHRQ-funded; HS026372.
Citation: Gelfand JM, Armstrong AW, Bell S .
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Vversion 1.
J Am Acad Dermatol 2020 Dec;83(6):1704-16. doi: 10.1016/j.jaad.2020.09.001..
Keywords: Skin Conditions, Chronic Conditions, Care Management, Evidence-Based Practice, Guidelines, COVID-19
Silverberg JI, Lai JS, Patel KR
Measurement properties of the Patient-Reported Outcomes Information System (PROMIS(®) ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
This study evaluated the validity of numeric rating scales (NRS) and verbal rating scales (VRS) for itch and itch frequency for assessing itch severity in atopic dermatitis (AD). The authors evaluated the Patient-Reported Outcomes Information System (PROMIS(®) ) Itch Questionnaire (PIQ) - itch severity assessment, including multiple NRS, VRS and frequency of itch assessments, in adults with AD and compared their performance. The evaluation involved self-administered questionnaires and skin examinations performed in 410 patients with AD (aged 18-90 years) in a dermatology practice setting. PIQ NRS, VRS and frequency of itch had good content validity, strong correlations with one another and weak-to-moderate correlations with patient-oriented eczema measure (POEM), Eczema Area and Severity Index (EASI), objective SCORing AD (SCORAD) and Dermatology Life Quality Index (DLQI) and very good discriminant validity.
AHRQ-funded; HS023011.
Citation: Silverberg JI, Lai JS, Patel KR .
Measurement properties of the Patient-Reported Outcomes Information System (PROMIS(®) ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
Br J Dermatol 2020 Nov;183(5):891-98. doi: 10.1111/bjd.18978..
Keywords: Skin Conditions, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes
Greenhawt M, Shaker M
Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction.
The authors sought to identify scenarios in which current early peanut introduction guidelines would be cost-effective. They found that the current screening approach to early peanut introduction could be cost-effective at a particular health utility for an in-clinic reaction, skin prick test sensitivity and specificity, and high baseline peanut allergy prevalence among high-risk infants. However, such conditions are unlikely to be plausible to achieve realistically. They recommend further research to define the health state utility associated with reaction location.
AHRQ-funded; HS024599.
Citation: Greenhawt M, Shaker M .
Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction.
JAMA Netw Open 2019 Dec 2;2(12):e1918041. doi: 10.1001/jamanetworkopen.2019.18041..
Keywords: Patient-Centered Outcomes Research, Newborns/Infants, Children/Adolescents, Respiratory Conditions, Skin Conditions, Screening, Healthcare Costs, Evidence-Based Practice, Guidelines
Vakharia PP, Chopra R, Silverberg NB
Efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts: a systematic review.
The objective of this systematic review was to assess the efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts. The investigators found that topical cantharidin demonstrated clearance of warts, particularly in combination with podophyllotixin and salicylic acid, and modest benefit for pediatric molluscum contagiosum with good tolerability and safety.
AHRQ-funded; HS023011.
Citation: Vakharia PP, Chopra R, Silverberg NB .
Efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts: a systematic review.
Am J Clin Dermatol 2018 Dec;19(6):791-803. doi: 10.1007/s40257-018-0375-4..
Keywords: Evidence-Based Practice, Skin Conditions, Treatments
Thorlacius L, Garg A, Ingram JR
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
This article describes the outcome of two in-person consensus meetings to create a core outcomes set (COS) for hidradenitis suppurative (HS) research. Forty-one individuals from 13 countries and 4 continents were included. The list of items discussed had been developed from patient interviews, a systematic literature review and a healthcare professional survey. Nine items were excluded and seven domains were approved which included: disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain and global assessments.
AHRQ-funded; HS024585.
Citation: Thorlacius L, Garg A, Ingram JR .
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
Br J Dermatol 2018 Mar;178(3):715-21. doi: 10.1111/bjd.16093..
Keywords: Evidence-Based Practice, Health Services Research (HSR), Outcomes, Research Methodologies, Skin Conditions
Greenhawt M, Fleischer DM, Chan ES
LEAPing through the looking glass: secondary analysis of the effect of skin test size and age of introduction on peanut tolerance after early peanut introduction.
This study explored relationships between peanut tolerance, baseline peanut/egg sensitization, eczema severity/duration, age of introduction, gender, and race. It concluded that increasing peanut wheal size predicted peanut tolerance only in the avoidance arm. Peanut introduction between 6 and 11 months of age was associated with the highest rates of peanut tolerance, questioning the 'urgency' of introduction before 6 months.
AHRQ-funded; HS024599.
Citation: Greenhawt M, Fleischer DM, Chan ES .
LEAPing through the looking glass: secondary analysis of the effect of skin test size and age of introduction on peanut tolerance after early peanut introduction.
Allergy 2017 Aug;72(8):1254-60. doi: 10.1111/all.13100.
.
.
Keywords: Evidence-Based Practice, Nutrition, Skin Conditions, Patient-Centered Outcomes Research
Kantor R, Kim A, Thyssen JP
Association of atopic dermatitis with smoking: a systematic review and meta-analysis.
The authors examined the association between atopic dermatitis (AD) and exposure to tobacco smoke. They found that a diagnosis of AD was associated with higher odds of active smoking and exposure to passive smoke but not to maternal smoking during pregnancy, and concluded that active and passive tobacco smoke exposure are associated with increased AD prevalence.
AHRQ-funded; HS023011.
Citation: Kantor R, Kim A, Thyssen JP .
Association of atopic dermatitis with smoking: a systematic review and meta-analysis.
J Am Acad Dermatol 2016 Dec;75(6):1119-25.e1. doi: 10.1016/j.jaad.2016.07.017.
.
.
Keywords: Skin Conditions, Tobacco Use, Risk, Evidence-Based Practice